Logo

Boehringer Ingelheim’s Jardiance Receives NICE Recommendation for Symptomatic Chronic Heart Failure with Preserved or Mildly Reduced Ejection Fraction

Share this
Boehringer

Boehringer Ingelheim’s Jardiance Receives NICE Recommendation for Symptomatic Chronic Heart Failure with Preserved or Mildly Reduced Ejection Fraction

Shots:

  • The NICE has issued its final draft guidance recommending Jardiance (empagliflozin) as an option for the treatment of symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults
  • The recommendation was based on the P-III (EMPEROR-Preserved) trial results evaluating Jardiance which demonstrated that empagliflozin achieved its primary composite EPs (CV death or hospitalization for HF) in adults with an ejection fraction of ≥40%
  • The NICE earlier advised empagliflozin in Mar 2022 for symptomatic chronic heart failure in patients with low ejection fraction. This recommendation will increase the usage of empagliflozin

Ref: Pharmaweb | Image: Boehringer

Related News:- Boehringer Ingelheim and Eli Lilly Receive EC’s Approval of Jardiance (empagliflozin) for the Treatment of Adults with Chronic Kidney Disease

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions